Monday, May 31, 2021

Glenmark expects 10-12% sales growth in FY22, anticipates value unlock of its RD business

Glenmark expects 10-12% sales growth in FY22, anticipates value unlock of its RD business Sale of anti-COVID drug Fabiflu and other products fire Q1 revenues; the company spends little over $100 million annually on innovation RD business, bigger than most of its peers, developing a potential pipeline of drug assets

from Moneycontrol Business News https://ift.tt/3i62RHe
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Short-term volatility may persist, but FII flows and economic activity to keep sentiment positive: Vikas Khemani

Vikas Khemani of Carnelian Asset Management remains optimistic about Indian markets, citing a strong domestic growth story and the resolutio...